Regulus Therapeutics is a San Diego-based biopharmaceutical company focused on developing microRNA-targeted drugs for orphan kidney diseases, including its candidate RGLS8429 for autosomal dominant polycystic kidney disease. The company went public on October 4, 2012, and has 28 employees.